Proliferation markers predictive of the pathological response and disease outcome of patients with breast carcinomas treated by anthracycline-based preoperative chemotherapy

European Journal of Cancer

Volumn 40, Issue 10, 2004, Pages 1502-1508

  Vincent Salomon, Anne ^a   Rousseau, Alexandra ^a   Jouve, Michel ^a   Beuzeboc, Philippe ^a   Sigal Zafrani, Brigitte ^a   Fréneaux, Paul ^a   Rosty, Christophe ^a   Nos, Claude ^a   Campana, François ^a   Klijanienko, Jerzy ^a   Al Ghuzlan, Abir ^a   Sastre Garau, Xavier ^a  

^a INSTITUT CURIE   (France)

Author keywords

Mitotic index; Pathological response; Predictive markers; Preoperative chemotherapy; Prognostic markers; Proliferation markers

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUOROURACIL; KI 67 ANTIGEN;

ADULT; ARTICLE; BREAST BIOPSY; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER SURVIVAL; CELL CYCLE S PHASE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE MARKER; EVALUATION; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MITOSIS; NEEDLE BIOPSY; PATHOLOGY; PREDICTION; PREOPERATIVE PERIOD; PRIORITY JOURNAL; PROGNOSIS; SAMPLING; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; CELL DIVISION; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; FLUOROURACIL; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LYMPHATIC METASTASIS; MIDDLE AGED; MITOTIC INDEX; PREOPERATIVE CARE; PROGNOSIS; SURVIVAL ANALYSIS;

EID: 2942521162     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejca.2004.03.014     Document Type: Article

References (31)

1. Bonadonna G., Valagussa P., Brambilla C., Ferrari L., Moliterni A., Terenziani M., et al. Primary chemotherapy in operable breast cancer: eight-year experience at the Milan Cancer Institute. J. Clin. Oncol. 16(1):1998;93-100
2. Viens P., Palangie T., Janvier M., Fabbro M., Roche H., Delozier T., et al. First-line high-dose sequential chemotherapy with rG-CSF and repeated blood stem cell transplantation in untreated inflammatory breast cancer: toxicity and response (PEGASE 02 trial). Br. J. Cancer. 81(3):1999;449-456
3. Chollet P., Charrier S., Brain E., Cure H., van Praagh I., Feillel V., et al. Clinical and pathological response to primary chemotherapy in operable breast cancer. Eur. J. Cancer. 33(6):1997;862-866
4. Sataloff D.M., Mason B.A., Prestipino A.J., Seinige U.L., Lieber C.P., Baloch Z. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast: a determinant of outcome. J. Am. Coll. Surg. 180(3):1995;297-306
5. Smith I.C., Heys S.D., Hutcheon A.W., Miller I.D., Payne S., Gilbert F.J., et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J. Clin. Oncol. 20(6):2002;1456-1466
6. Brain E., Garrino C., Misset J., Garcia Carbonero I., Itzhaki M., Cvitkovic E., et al. Long-term prognostic and predictive factors in 107 stageII/III breast cancer patients treated with anthracycline-based neoadjuvant chemotherapy. Br. J. Cancer. 75:1997;136061367
7. Feldman L.D., Hortobagyi G.N., Buzdar A.U., Ames F.C., Blumenschein G.R. Pathological assessment of response to induction chemotherapy in breast cancer. Cancer Res. 46(5):1986;2578-2581
8. Fisher B., Bryant J., Wolmark N., Mamounas E., Brown A., Fisher E., et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J. Clin. Oncol. 16:1998;2672-2685
9. Chevallier B. Inflammatory breast cancer. Bull. Cancer. 80(12):1993;1024-1034
10. Fisher E.R., Wang J., Bryant J., Fisher B., Mamounas E., Wolmark N. Pathobiology of preoperative chemotherapy: findings from the National Surgical Adjuvant Breast and Bowel (NSABP) protocol B-18. Cancer. 95(4):2002;681-695
11. Vincent-Salomon A., Carton M., Freneaux P., Palangie T., Beuzeboc P., Mouret E., et al. ERBB2 overexpression in breast carcinomas: no positive correlation with complete pathological response to preoperative high-dose-anthracycline-based chemotherapy. Eur. J. Cancer. 36:2000;586-591
12. Faneyte I.F., Schrama J.G., Peterse J.L., Remijnse P.L., Rodenhuis S., van de Vijver M.J. Breast cancer response to neoadjuvant chemotherapy: predictive markers and relation with outcome. Br. J. Cancer. 88(3):2003;406-412
13. Bertheau P., Plassa F., Espie M., Turpin E., de Roquancourt A., Marty M., et al. Effect of mutated TP53 on response of advanced breast cancers to high-dose chemotherapy. Lancet. 360(9336):2002;852-854
14. Muss H., Thor A., Berry D., Kute T., Liu E., Koerner F., et al. c-erbB-2 Expression and response to adjuvant therapy in women with node-positive early breast cancer. New Eng. J. Med. 330:1994;1260-1266
15. Makris A., Powles T.J., Dowsett M., Osborne C.K., Trott P.A., Fernando I.N., et al. Prediction of response to neoadjuvant chemoendocrine therapy in primary breast carcinomas. Clin. Cancer Res. 3(4):1997;593-600
16. MacGrogan G., Mauriac L., Durand M., Bonichon F., Trojani M., de Mascarel I., et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MiB1, pS2 and GST pi. Br. J. Cancer. 74(9):1996;1458-1465
17. Wang J., Buchholz T.A., Middleton L.P., Allred D.C., Tucker S.L., Kuerer H.M., et al. Assessment of histologic features and expression of biomarkers in predicting pathologic response to anthracycline-based neoadjuvant chemotherapy in patients with breast carcinoma. Cancer. 94(12):2002;3107-3114
18. MacGrogan G., Pallud C., Simony-Lafontaine J., Antoine M., Ettore F., Verrielle V., et al. Pathological and clinical predictors for response to neoadjuvant chemotherapy in breast cancer. Mod. Pathol. 16:2003;. Abstract
19. Colleoni M., Orvieto E., Nole F., Orlando L., Minchella I., Viale G., et al. Prediction of response to primary chemotherapy for operable breast cancer. Eur. J. Cancer. 35(4):1999;574-579
20. Chang J., Powles T.J., Allred D.C., Ashley S.E., Clark G.M., Makris A., et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J. Clin. Oncol. 17(10):1999;3058-3063
21. Remvikos Y., Beuzeboc P., Zajdela A., Voillemot N., Magdelenat H., Pouillart P. Correlation of pretreatment proliferative activity of breast cancer with response to cytotoxic chemotherapy. J. Natl. Cancer Inst. 81:1989;1383-1387
22. Spyratos F., Briffod M., Tubiana-Hulin M., Andrieu C., Mayras C., Pallud C., et al. Sequential cytopunctures during preoperative chemotherapy for primary breast carcinoma. II. DNA flow cytometry changes during chemotherapy, tumor regression and short-term follow-up. Cancer. 69(2):1992;470-475
23. Billgren A.M., Rutqvist L.E., Tani E., Wilking N., Fornander T., Skoog L. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol. 38(5):1999;597-601
24. Ellis P.A., Smith I.E., McCarthy K., Detre S., Salter J., Dowsett M. Preoperative chemotherapy induces apoptosis in early breast cancer. Lancet. 349(9055):1997;849
25. Remvikos Y., Mosseri V., Asselain B., Fourquet A., Durand J.C., Pouillart P., et al. S-phase fractions of breast cancer predict overall and post-relapse survival. Eur. J. Cancer. 33(4):1997;581-586
26. van Diest P.J., Baak J.P., Matze-Cok P., Wisse-Brekelmans E.C., van Galen C.M., Kurver P.H., et al. Reproducibility of mitosis counting in 2, 469 breast cancer specimens: results from the multicenter morphometric mammary carcinoma project. Hum. Pathol. 23(6):1992;603-607
27. Colleoni M., Curigliano G., Minchella I., Peruzzotti G., Nole F., Mazzarol G., et al. Preoperative and perioperative chemotherapy with 5-fluorouracil as continuous infusion in operable breast cancer expressing a high proliferation fraction: cytotoxic treatment during the surgical phase. Ann. Oncol. 14(10):2003;1477-1483
28. Scholl S.M., Pierga J.Y., Asselain B., Beuzeboc P., Dorval T., Garcia-Giralt E., et al. Breast tumour response to primary chemotherapy predicts local and distant control as well as survival. Eur. J. Cancer. 31A(12):1995;1969-1975
29. Rozan S., Vincent-Salomon A., Zafrani B., Validire P., De Cremoux P., Bernoux A., et al. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer. Int. J. Cancer. 79(1):1998;27-33
30. Ellis P., Smith I., Ashley S., Walsh G., Ebbs S., Baum M., et al. Clinical prognostic and predictive factors for primary chemotherapy in operable breast cancer. J. Clin. Oncol. 16(1):1998;107-114
31. Dowsett M., Smith I.E., Salter J., Ellis P.A., Johnston S.R.D., Makris A., et al. Biological studies in primary medical therapy of breast cancer: the royal marsden hospital experience. Prim. Med. Ther. Breast Cancer. 4:1999;113-125